After Hours Gainer
NBTX Nanobiotix S.A. - Adss10.20+0.46+4.8%
After Hours:16.73+6.53 (+64.0%)
NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
Globe NewswireWed, 17-Sep 4:15 PM
After Hours:17.13+6.93 (+67.9%)
NBTX Nanobiotix S.A. - Adss5.38-0.14-2.5%
After Hours:5.61+0.23 (+4.3%)
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
Globe NewswireWed, 17-Apr 4:15 PM
After Hours Decliner
NBTX Nanobiotix S.A. - Adss6.68+4.65+229.1%
After Hours:6.28-0.40 (-6.0%)
NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company
Globe NewswireFri, 5-May 1:30 AM
After Hours:6.10-0.58 (-8.7%)
